BBIO vs IONS
BridgeBio Pharma, Inc. and Ionis Pharmaceuticals, Inc., both Healthcare
BridgeBio Pharma, Inc. is the larger company at $14B against $13B. Over the past year BBIO returned +25% against -26% for IONS. The RyuScore puts IONS ahead, 17 against 7 out of 100.
| Figure | BBIO | IONS |
|---|---|---|
| Last close | $65.35 | $45.26 |
| Market cap | $14B | $13B |
| 1-year return | +25% | -26% |
| 5-year return | +34% | +25% |
| RyuScoresector-relative, 1–10 | 7/100 | 17/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
BridgeBio Pharma, Inc.
Revenue of $244M in Q2 2026, net income null. Its largest reported line is License Services And Royalty, 45% of the disclosed total.
Ionis Pharmaceuticals, Inc.
Revenue of $268M in Q2 2026, net income null. Its largest reported line is Royalty, 28% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or see the correlation.